ICON is a global contract research organization (CRO) that runs clinical trials and related development services for pharmaceutical, biotech and medical-device companies. Its offerings span trial design, site and patient recruitment, data management, regulatory support and full-program outsourcing across therapeutic areas. Scale after major industry consolidation, including the combination with PRA Health Sciences, positions it among the largest end-to-end clinical research partners.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2,039.1 | — | 203.5 | — |
| Q3 2025 | 2,084.4 | — | -284.2 | — |
| Q4 2025 | 2,189.8 | — | -110.1 | — |
| Q1 2026 | 2,034 | — | 104.8 | — |
| Q2 2026 | 2,063.5 | 1.2% | 72.6 | -64.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: CoStar Group, Inc. (CSGP), Sterling Infrastructure, Inc. (STRL), BridgeBio Pharma, Inc. (BBIO), The Carlyle Group Inc. (CG), Manhattan Associates, Inc. (MANH), Semtech Corporation (SMTC)